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ouston, Texas
ntiplatelet therapy with the thienopyridine clopidogrel has
njoyed unprecedented success over the last decade. Ther-
py with clopidogrel now forms an integral part of nearly all
ntracoronary stenting procedures, and long-term clopi-
ogrel is generally recommended for patients who have had
rug-eluting stents placed. The background of clopidogrel is
ather unusual. The “early” work on stent placement was
erformed with a combination of aspirin and the thienopy-
idine ticlopidine (1,2). However, it soon became apparent
hat, whereas ticlopidine was not well tolerated, clopidogrel
as much less noxious and seemed to be similarly effective
3). Paradoxically, this development occurred in the absence
f randomized trials comparing its efficacy with that of
iclopidine. More recent developments surrounding clopi-
ogrel have centered on the appropriate dosing of the drug
See pages 612 and 620
nd the identification of patients with suboptimal biologic
esponses (4-6). In fact, if one looks at the earliest dosing
tudies that were used to support clopidogrel’s regulatory
pproval, it is remarkable to note that doses as low as 25 to
0 mg were initially explored (7). Currently, we know that
dministration of a 75-mg dose of clopidogrel causes steady
tate inhibition of the platelet aggregation response to
denosine diphosphate at 24 h, that the response after 300
g seems to plateau at 6 h, and that the response to 600 mg
ears its maximal value at 2 h. Two subsequent studies have
ndicated that the response in patients undergoing percuta-
eous coronary intervention (PCI) does not occur more
uickly or become more intense when the dose is raised
rom 600 to 900 mg (8,9).
Although these principles seem simple enough, recent
tudies indicate the situation is much more complex. Clo-
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
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tudy.idogrel is a pro-drug that is converted in the liver by
embers of the cytochrome P450 (CYP) 3A, 1A, 2B, and
C subfamilies. The metabolism of the drug involves a
eries of intermediate metabolites ultimately yielding the
ctive thiol metabolite, which binds to the platelet puriner-
ic receptor known as P2Y12. Common teaching recently
as been that the metabolism of clopidogrel is “bottle-
ecked” in the liver; the findings of the ISAR (Intracoronary
tenting and Antithrombotic Regimen) trial group seem to
onfirm this belief. After increasing the loading dose of
lopidogrel from 600 mg to 900 mg, von Beckerath et al. (8)
eported that levels of the active metabolite were no differ-
nt between the 2 groups. Recently, Bonello et al. (10)
emonstrated that measurements of vasodilator stimulated
hosphoprotein (VASP) could be used to titrate the loading
ose when sequential doses of 600 mg separated by approx-
mately 24 h were given to patients who had a suboptimal
esponse as determined with the VASP or platelet reactivity
ndex (PRI).
In the current issue of JACC: Cardiovascular Interventions,
hese fundamental beliefs are revisited and expanded
11,12). The PRINC (Plavix Response in Coronary Inter-
ention) trial investigators tested a novel dosing scheme for
lopidogrel. In this study, 60 patients undergoing PCI
eceived a 600-mg loading dose of clopidogrel and were
hen randomized to receive, 2 h later, either a second
00-mg dose or a placebo (there was also a randomization to
ntracoronary verapamil that had little effect on any mea-
urable platelet parameter.) Patients were rerandomized the
ext day to receive a daily dose of either 75 mg or 150 mg
or 7 days. The principal finding was that, 2 h after the
econd dose of clopidogrel or placebo was given, platelet
ggregation measured with the VerifyNow agglutination
ssay was more inhibited among patients treated with 2
oading doses of clopidogrel than a single loading dose (42%
s. 24%, p  0.01). The log-transformed rate of increase in
latelet inhibition was also 3-fold greater during the 2 h
fter the second dose was given. At 7 days, aggregation was
lso more inhibited among patients treated with 150 mg
aily compared with 75 mg daily (50% vs. 29%, p  0.01).
f confirmed, these findings will add another dimension to
ur understanding of clopidogrel dosing, because they
uggest that timing of the loading dose might be as
mportant as the total quantity given. In other words, while
ncreasing a single loading dose of clopidogrel beyond 600
g does not increase activity of the drug, it now seems that
taggering the increase does exactly this. In fact, closer
nspection of the findings of von Beckerath et al. (8)
ndicates that neither levels of the active metabolite nor
evels of the parent compound increase when a single
oading dose exceeds 600 mg. Whereas attention largely had
ocused on the CYP family of enzymes and metabolic
ctivation of clopidogrel, these findings should also impress
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629n us the importance of absorption and transport of the
rug from the intestinal lumen.
In a second report from this study, the PRINC investi-
ators tie these findings to genotypic variation in the
harmacodynamics of clopidogrel. With a candidate gene
pproach, they identified carriers within the study of a
umber of common alleles known to be associated with loss
r gain of CYP function or intestinal absorption. The size of
heir study precluded analyses of some rarer polymorphisms.
mong patients with the wild-type 2C19 allele (2C19*1*1),
latelet aggregation responses to the 600-mg single dose
nd the 1,200-mg staggered dose were similar, as were
esponses to the 75- and 150-mg maintenance doses. In
ontrast, carriers of the loss of function alleles, 2C19*2 and
C19*4, had lower aggregation responses than 2C19*1*1
ubjects. Unlike the 2C19*1*1 subjects, they also had a
reater response to the staggered loading dose than to the
ingle 600-mg dose and also had more inhibition of aggre-
ation after 7 days of a 150-mg versus 75-mg maintenance
ose. Carriers of the 2C9*2 and -*3 alleles also had less
esponse than subjects with 2C9*1*1 genotypes. In other
ords, increasing the loading dose in a staggered fashion
ad its greatest impact in patients who carried alleles
ssociated with diminished CYP 2C9 or 2C19 function.
he study also yielded 2 surprising findings: first, carriers of
YP 2C19*17, an allele associated with marked gain of
nzyme function, did not have a heighted response to
lopidogrel; second, a well-characterized mutation of the
-glycoprotein (P-gp) efflux transport protein (which shares
onsiderable substrate specificity with CYP 3A4) was asso-
iated with only a minimal trend toward increased response
o clopidogrel. The P-gp is believed to play an important
ole in the reverse transport of absorbed clopidogrel (as well
s other drugs) from the intestinal wall back into the
ntestinal lumen. This finding is in contrast to the report by
aubert et al. (13), which showed a 2.5-fold decrease in the
max of clopidogrel and 2-fold decrease in its active
etabolite among individuals with the MDR1 3435 T/T
enotype, which is a loss of function mutation of P-gp.
lthough the 2 former unexpected findings might simply be
he result of a small sample size, they are particularly
urprising in a study that seems to highlight the importance
f absorption kinetics.
Interventionalists who fear that their lives are becoming
ncreasingly complex should be aware of one simple fact—it
s. Now, in addition to whether a 300- or 600-mg loading
ose of clopidogrel is indicated, the clinician must also be
ware of multiple drugs that interact with clopidogrel, such
s atorvastatin (14), omeprazole (15), calcium channel
ntagonists, and even coffee (16) and cigarette smoke (17);
he importance of staggering a clopidogrel loading dose; and
enetic variants of the enzymes that regulate metabolism
nd possibly absorption of clopidogrel, not to mention the
omplexity of deciding whether to measure platelet response No clopidogrel. Even the current reports from the PRINC
nvestigation leave several important questions unanswered.
or example, is the correct number of loading doses 2, or
ould 3 or 4 staggered doses lead to even higher levels of
latelet inhibition? Should 150 mg be given as a single daily
aintenance dose or, given the approximate 1- to 2-h
alf-life of the active metabolite (18), would split (twice
aily) dosing be more effective, because platelets freshly
eleased from the bone marrow might then be exposed to a
econd dose later in the day? Is 150 mg daily given as a
ingle dose for 7 days long enough to produce a meaningful
linical result, or might not a longer course of 150 mg be
ore effective? Finally, there are 2 overwhelmingly impor-
ant questions that these studies do not even address. Is
here a bona fide clinical indication for measuring platelet
ggregation or agglutination in patients receiving clopi-
ogrel (or even genotyping them for known CYP alleles)?
ow would platelet inhibition with this strategy stack up
gainst more potent antagonists of P2Y12 that have less
ariable effects, such as prasugrel or AZD6140?
All semblance of sanity should not be abandoned, how-
ver. All of the observations described in the preceding
aragraph must be regarded as exploratory. Although much
ttention has been paid to observations that myocardial
nfarction and stent thrombosis are more common in
atients characterized as clopidogrel non-responders, it is
mportant not to lose sight of fundamental clinical princi-
les. Several findings from clinical databases suggest that
ot all interventions that alter the platelet response to
lopidogrel have much clear clinical relevance. For example,
he in vitro interaction between clopidogrel and atorvastatin
as not been shown to influence the risk of ischemic events
n several large clinical databases (19,20). Similarly, al-
hough the investigators of the ISAR reloading study
eported that in patients maintained on maintenance clopi-
ogrel reloading with a 600-mg dose led to further inhibi-
ion of platelet aggregation (21), the ARMYDA (Antiplate-
et Therapy for Reduction of Myocardial Damage During
ngioplasty) trial investigators performed a randomized
linical trial in which this strategy had no effect on outcomes
22). Preliminary clinical studies of the effect of CYP
enotype have also been disappointing. Trenk et al. (23)
eported that CYP 2C19*2 carriers were more likely to have
ncreased platelet reactivity while on clopidogrel, and that
ncreased platelet reactivity was associated with a higher
vent rate 1 year after coronary stenting. However, the most
mportant link, a clinical association between CYP 2C19
enotype and clinical events (death and myocardial infarc-
ion), was not detected, possibly as a consequence of the
nfrequency of events.
Thus there is good reason for equipoise among interven-
ionalists who need to know more about clopidogrel dosing.
he GRAVITAS (Gauging Responsiveness with A Verify
ow Assay–Impact on Thrombosis and Safety) study will
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630xamine, in 6,600 patients undergoing PCI, the clinical
mportance of a poor platelet aggregation response to
lopidogrel and will test whether increasing the mainte-
ance dose of clopidogrel to 150 mg daily will be of clinical
enefit (24). The OASIS 7 (Organization for the Assess-
ent of Strategies for Ischemic Syndromes) study will
ompare a 300-mg loading dose of clopidogrel with a
00-mg loading dose, and will compare a 75-mg mainte-
ance dose for 7 days with a 150-mg dose (25). Therefore it
eems that some clarity will come to this issue, albeit slowly.
eprint requests and correspondence: Dr. Neal S. Kleiman,
ethodist DeBakey Heart Center, Department of Cardiology,
he Methodist Hospital, 6565 Fannin, F-1035, Houston, Texas
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